Lassa Fever - Pipeline Insight, 2024

This “Lassa Fever - Pipeline Insight, 2024,” report provides comprehensive insights about companies and pipeline drugs in the Lassa Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lassa Fever Understanding

Lassa Fever: Overview

Lassa fever or Lassa Hemorrhagic fever is an animal-borne, or zoonotic, acute viral illness caused by Lassa virus, a member of the arenavirus family of viruses. The illness was discovered in 1969 and is named after the town Lassa in Nigeria where the first cases occurred. It is spread to people through contact with household items, food, water, or air contaminated with the droppings or urine of infected multimammate rats. The disease is endemic in the rodent population in parts of West Africa. Lassa fever is known to be endemic in Benin, Ghana, Guinea, Liberia, Mali, Sierra Leone, Togo and Nigeria, but probably exists in other West African countries as well.

Symptoms
Symptoms of Lassa fever and South American arenavirus hemorrhagic fevers usually start about 5 to 16 days after people are exposed to the virus. These infections cause fever, a general feeling of illness (malaise), weakness, diffuse body aches, diarrhea, and vomiting. Over the next 4 to 5 days, chest pain, a sore throat, cough, and vomiting may develop. About 80% of cases of Lassa fever are mild and are often not diagnosed. But symptoms are severe in about 20% of people. If severe Lassa fever may cause the face and neck to swell. About 20% of people with Lassa fever lose their hearing. Loss may be permanent.

Diagnosis
Lassa fever is most often diagnosed by using enzyme-linked immunosorbent serologic assays (ELISA), which detect IgM and IgG antibodies as well as Lassa antigen. Reverse transcription-polymerase chain reaction (RT-PCR) can be used in the early stage of disease.

Treatment
Rehydration and treatment of symptoms can improve the chances of survival if there is an early diagnosis. Ribavirin, an antiviral drug, has been used with success in Lassa fever patients. It has been shown to be most effective when given early in the course of the illness. Supportive care consisting of maintenance of appropriate fluid and electrolyte balance, oxygenation and blood pressure is also one way to prevent the spread of Lassa virus.

Lassa Fever Emerging Drugs Chapters

This segment of the Lassa Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lassa Fever Emerging Drugs

INO-4500: Inovio PharmaceuticalsINO-4500 is a DNA-encoded monoclonal antibody (dMAb™) immunotherapy vaccine candidate. It is being clinically tested in Phase I for the prevention of lassa fever in collaboration with Coalition for Epidemic Preparedness Innovations (CEPI).

MV-LASV : Themis Bioscience GmbHMV-LASV vaccine candidate is a recombinant, live-attenuated, viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection. MV-LASV vaccine candidate is indicated for at-risk populations during outbreaks of Lassa Fever. Themis has begun Phase I trials for MV-LASV for treating Lassa Fever.

LHF 535: Kineta, IncLHF-535 is an oral antiviral with potent activity against Lassa fever and other arenaviruses. Its mechanism of action involves inhibiting virus entry into target host cells and suppressing viral replication. LHF-535 is once a daily oral therapeutic agent well-tolerated in preclinical studies and currently in Phase I stage of development in collaboration with National Institutes of Allergy and infectious disease.

Lassa Fever: Therapeutic Assessment

This segment of the report provides insights about the different Lassa Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lassa Fever

There are approx. 10+ key companies which are developing the therapies for Lassa Fever. The companies which have their Lassa Fever drug candidates in the mid to advanced stage, i.e. phase I and Preclinical include, Inovio Pharmaceuticals and others.

Phases

This report covers products under different phases of clinical development like

• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lassa Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intramuscular
• Intradermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Vaccines
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lassa Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase I, preclinical and discovery stage. It also analyses Lassa Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lassa Fever drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Lassa Fever R&D. The therapies under development are focused on novel approaches to treat/improve Lassa Fever.

Lassa Fever Report Insights

• Lassa Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lassa Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lassa Fever drugs?
• How many Lassa Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lassa Fever?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lassa Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lassa Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Curevac AG
• Themis Bioscience
• Inovio Pharmaceuticals
• GeoVax
• GloBavir biosciences Inc.
• Kineta Inc.

Key Products

• IN4500
• MV-LASV
• GBV006
• GEO-LM01
• LHF 535
• rVSV Lassa

This product will be delivered within 2 business days.